Literature DB >> 7929363

Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CD18.

P J Muchowski1, L Zhang, E R Chang, H R Soule, E F Plow, M Moyle.   

Abstract

Neutrophil inhibitory factor (NIF) is a hookworm-derived glycoprotein ligand of the integrin CD11b/CD18 that inhibits human neutrophil function (Moyle, M., Foster, D. L., McGrath, D. E., Brown, S. M., Laroche, Y., De Meutter, J., Stanssens, P., Bogowitz, C. A., Fried, V. A., Ely, J. A., Soule, H. R., and Vlasuk, G. P. (1994) J. Biol. Chem. 269, 1008-10015). Here, we present evidence that recombinant NIF (rNIF) associates with the approximately 200-amino acid residue I domain of CD11b/CD18 and that this interaction is essential for inhibition of neutrophil function by NIF. First, radiolabeled rNIF binds to a recombinant glutathione S-transferase fusion protein that contains the CD11b I domain. This high affinity interaction has a partial dependence on divalent cations. The association of rNIF with the CD11b I domain is specific because 125I-rNIF does not bind either a glutathione S-transferase fusion protein that contains the I domain of the integrin CD11a/CD18 or recombinant glutathione S-transferase without the I domain. Second, the CD11b I domain fusion protein effectively competes with CD11b/CD18 on human neutrophils for 125I-rNIF binding. Third, the CD11b I domain fusion protein blocks the inhibition of certain neutrophil functions by rNIF, including adhesion of neutrophils to human endothelial cell monolayers and adhesion-dependent release of hydrogen peroxide from neutrophils. Specificity is demonstrated by the inability of the CD11a I domain fusion protein to block either rNIF binding to neutrophils or rNIF activity. Fourth, rNIF blocks the interaction between neutrophils and fibrinogen, a CD11b/CD18 ligand that is also thought to bind the I domain of CD11b. In contrast, rNIF does not appear to block the binding of factor X to CD11b/CD18 on neutrophils. These results suggest that CD11b/CD18 has multiple distinct binding sites for its cognate ligands, including, but not limited to, the I domain. NIF interferes with the binding of a subset of these CD11b/CD18 ligands in a highly selective manner.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929363

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics.

Authors:  Chunzhang Cao; Daniel A Lawrence; Dudley K Strickland; Li Zhang
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

2.  Mac-1 promotes FcgammaRIIA-dependent cell spreading and migration on immune complexes.

Authors:  Ying Xiong; Chunzhang Cao; Alexandra Makarova; Brad Hyman; Li Zhang
Journal:  Biochemistry       Date:  2006-07-25       Impact factor: 3.162

3.  The structure of hookworm platelet inhibitor (HPI), a CAP superfamily member from Ancylostoma caninum.

Authors:  Dongying Ma; Ivo M B Francischetti; Jose M C Ribeiro; John F Andersen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-05-20       Impact factor: 1.056

4.  Molecular basis for the interaction of low density lipoprotein receptor-related protein 1 (LRP1) with integrin alphaMbeta2: identification of binding sites within alphaMbeta2 for LRP1.

Authors:  Sripriya Ranganathan; Chunzhang Cao; Jason Catania; Molly Migliorini; Li Zhang; Dudley K Strickland
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

Review 5.  Clinical Trials of Immunomodulation in Ischemic Stroke.

Authors:  Roland Veltkamp; Dipender Gill
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 6.  Pathobiology of neutrophil-epithelial interactions.

Authors:  Jennifer C Brazil; Charles A Parkos
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

7.  Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor.

Authors:  D Borden Lacy; Darran J Wigelsworth; Heather M Scobie; John A T Young; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 8.  Leukocyte integrins and their ligand interactions.

Authors:  Young-Min Hyun; Craig T Lefort; Minsoo Kim
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

9.  In vivo expression of neutrophil inhibitory factor via gene transfer prevents lipopolysaccharide-induced lung neutrophil infiltration and injury by a beta2 integrin-dependent mechanism.

Authors:  M Y Zhou; S K Lo; M Bergenfeldt; C Tiruppathi; A Jaffe; N Xu; A B Malik
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.